ArticleScientific reports2025
NIPAL4 is an important marker for clear cell renal cell carcinoma prognosis and immunotherapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-driven radiogenomic analysis of clear cell renal cell carcinoma: perinephric adipose tissue stranding as a key feature of the NIPAL4-associated imaging pattern.The Canadian journal of urology · 2025Article
- Identification and Experimental Validation of Prognostic Signature and Peroxisome-Related Key Genes in Clear Cell Renal Cell Carcinoma.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) poses significant clinical challenges due to its high metastatic rate at diagnosis and resistance to conventional therapies. The magnesium transporter NIPAL4, involved in lipid metabolism and magnesium ion homeostasis, has recently been implicated in cancer biology but remains understudied in ccRCC. In this study, we identifies NIPAL4 as a potential prognostic marker and therapeutic target in ccRCC. High NIPAL4 expression is associated with poor prognosis and contributes to tumor proliferation and migration. Bioinformatics analyses indicate that NIPAL4 is involved in critical pathways related to the extracellular matrix, lipid metabolism, and the TGF-β signaling pathway. Moreover, NIPAL4's association with immune cell infiltration and immune checkpoint molecules highlights its potential as an immunotherapy marker. These findings warrant further investigation into NIPAL4's role in ccRCC to develop more effective treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.